{"product_id":"infusystem-pestle-analysis","title":"InfuSystem PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how regulatory shifts, reimbursement trends, and tech-driven care models are influencing InfuSystem’s growth and risks in our concise PESTLE snapshot—designed for investors and strategists who need clarity fast. Purchase the full PESTLE Analysis to unlock detailed, actionable insights and downloadable templates you can use immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reimbursement Policy Changes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChanges in Medicare and Medicaid reimbursement rates can swing InfuSystems' oncology and pain management revenue materially; a 1% CMS rate cut would reduce its 2025 projected service revenue (FY2024 revenue $185.6M) by roughly $1.8M annually if exposure is proportional.\u003c\/p\u003e\n\u003cp\u003eFederal shifts expanding home infusion coverage—like increased Medicare Part B support—could raise InfuSystems' addressable market from an estimated 2.5M to 3.2M eligible patients, boosting long-term growth.\u003c\/p\u003e\n\u003cp\u003eMonitoring Social Security Act amendments is essential: prior CMS rule changes trimmed margins by ~120–180 bps for similar providers, risking compressed EBITDA unless reimbursments or operational efficiencies offset them.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernmental Healthcare Spending Priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpfederal budget allocations for cancer and chronic disease management reached approximately billion in nih related programs influencing grant availability infusion services devices. as federal cms policies push outpatient home-based care to curb inpatient costs spending on home health rose could capture increased demand equipment. political moves toward public options or expanded medicare shift purchasing larger centralized suppliers intensifying competition private providers like infusystem.\u003e\n\u003c\/pfederal\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade Policies and Medical Device Tariffs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInternational trade agreements and tariffs on electronic components and medical-grade materials can raise procurement costs for infusion pumps; US tariffs imposed on certain Chinese electronics averaged 7.5% in 2024, potentially increasing parts costs for InfuSystem by an estimated 2–4% of COGS. Political instability in manufacturing regions like Xinjiang and parts of Southeast Asia has correlated with 12–18% longer lead times in 2023–2024, risking hardware shortages. Strategic sourcing—diversifying suppliers and nearshoring—remains a priority to mitigate fluctuations in US-global trade relations and preserve gross margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA Regulatory Oversight and Approval Processes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe political climate around the FDA shapes device clearance timelines; in 2024 the FDA averaged 197 days for 510(k) decisions and 322 days for PMA reviews, affecting InfuSystem’s time-to-market and revenue recognition.\u003c\/p\u003e\n\u003cp\u003eStricter post-market safety mandates or expanded Breakthrough Device Program use can accelerate or delay launches—InfuSystem’s 2023 device revenue was $62.4M, sensitive to approval pace.\u003c\/p\u003e\n\u003cp\u003eExecutive leadership changes shift enforcement priorities; FDA inspection counts rose 12% in 2022–24, increasing compliance costs for medical service providers like InfuSystem.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA avg review: 197 days (510k), 322 days (PMA) in 2024\u003c\/li\u003e\n\u003cli\u003eInfuSystem device revenue: $62.4M (2023)\u003c\/li\u003e\n\u003cli\u003eFDA inspections up 12% (2022–24), raising compliance risk\/cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-Level Healthcare Regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVariations in state licensing for medical equipment providers force InfuSystem to tailor compliance across 40+ state regimes, raising operating costs and slowing rollouts; InfuSystem reported 2024 revenue of $154.4M, making regulatory efficiency material to margins.\u003c\/p\u003e\n\u003cp\u003eCertificate of Need laws in roughly 36 states can limit new service sites, constraining expansion and capital deployment decisions for InfuSystem when pursuing growth in high-demand regions.\u003c\/p\u003e\n\u003cp\u003eNavigating disparate biomedical service certification mandates demands significant admin resources and local political engagement, contributing to elevated SG\u0026amp;A and compliance spend that impacts EBITDA conversion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e40+ state licensing regimes\u003c\/li\u003e\n\u003cli\u003e~36 states with CON laws\u003c\/li\u003e\n\u003cli\u003e2024 revenue $154.4M—regulatory efficiency affects margins\u003c\/li\u003e\n\u003cli\u003eHigher SG\u0026amp;A\/compliance reduces EBITDA conversion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicaid cuts vs home-infusion growth: $1.8M risk, bigger market, regulatory drag\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical risks center on Medicare\/Medicaid rate changes (1% CMS cut ≈ $1.8M hit vs FY2024 service revenue $185.6M), expanded home-infusion coverage enlarging addressable market (2.5M→3.2M patients), FDA review times (197 days 510(k), 322 days PMA) affecting device revenue ($62.4M 2023), state licensing\/CON regimes (40+ states; ~36 CON) raising SG\u0026amp;A and compressing EBITDA.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 service rev\u003c\/td\u003e\n\u003ctd\u003e$185.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice rev 2023\u003c\/td\u003e\n\u003ctd\u003e$62.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS cut 1% impact\u003c\/td\u003e\n\u003ctd\u003e≈$1.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e510(k)\/PMA avg (2024)\u003c\/td\u003e\n\u003ctd\u003e197d \/ 322d\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStates licensing\/CON\u003c\/td\u003e\n\u003ctd\u003e40+ \/ ~36\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect InfuSystem across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by current data and trends to identify threats and opportunities for executives, consultants, and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clean, visually segmented PESTLE snapshot of InfuSystem for quick sharing in meetings or slide decks, using plain language so teams can rapidly align on external risks and strategic implications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressure on Operating Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising logistics, specialized labor, and medical-supply inflation—U.S. PPI for medical equipment up 6.2% YoY (2024) and freight rates ~12% above 2022—compress InfuSystem margins if increases cannot be passed to clients.\u003c\/p\u003e\n\u003cp\u003eEfficient fleet management of ~40,000 infusion pumps and tighter spare-part sourcing are essential as maintenance costs rose ~8%–10% in 2023–2024.\u003c\/p\u003e\n\u003cp\u003eHigh inflation erodes purchasing power of small clinics: 2024 Medicaid\/clinic operating margins averaged under 3%, limiting ability to absorb rental-price hikes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Fluctuations and Capital Expenditure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInterest rate increases raise InfuSystem's cost of debt for financing its sizable medical device inventory; a 1% rise can meaningfully lift annual interest expense on equipment-backed loans, squeezing margins given the company’s capital-intensive rental model.\u003c\/p\u003e\n\u003cp\u003eHigher rates curb expansion of the rental fleet and delay investments in biomedical service facilities, while rate stabilization—U.S. federal funds near 5.25% in 2024—enables more aggressive acquisitions and capital spending.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShift Toward Outpatient and Home Care Economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShift from inpatient to outpatient\/home care benefits InfuSystem, with US home healthcare spending rising to $157B in 2023 and projected 4.8% CAGR through 2028, lowering per-patient costs vs hospital stays by up to 60% and favoring outpatient infusion economics.\u003c\/p\u003e\n\u003cp\u003ePayers increasingly reimburse home infusion—Medicare Part B growth in home infusion claims rose ~12% in 2022–24—driving incentives to reduce system-wide costs and boosting demand for InfuSystem services.\u003c\/p\u003e\n\u003cp\u003eLong-term tailwinds support InfuSystem’s oncology and wound-care segments, which represented roughly 65% of 2024 revenue, positioning the company to capture shifting volume toward lower-cost settings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market Dynamics for Specialized Technicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe U.S. faced a shortage of biomedical technicians with projected shortfall ~15% by 2025, pushing median technician wages up ~6-8% YoY; InfuSystem's service model depends on these skilled hires, increasing labor expense risk and margin pressure.\u003c\/p\u003e\n\u003cp\u003eRetention requires competitive packages—InfuSystem may need to raise pay and training spend, affecting operating margins and potentially increasing SG\u0026amp;A relative to revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e15% projected technician shortfall by 2025\u003c\/li\u003e\n\u003cli\u003e6-8% YoY median wage growth for technicians\u003c\/li\u003e\n\u003cli\u003eHigher SG\u0026amp;A and margin pressure from increased compensation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation within the Healthcare Provider Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConsolidation of oncology practices into larger health systems reduces InfuSystem’s bargaining power as 2024 saw hospital system M\u0026amp;A transactions total roughly $60 billion, prompting centralized procurement that favors fewer suppliers.\u003c\/p\u003e\n\u003cp\u003eLarge networks negotiate long-term contracts offering volume discounts—US hospital systems spent about $450 billion on supplies in 2023—creating stable revenue but pressuring margins.\u003c\/p\u003e\n\u003cp\u003eMonitoring customers’ finances is critical: 2024 nonprofit hospital operating margins averaged 1.2%, indicating constrained capital expenditure and potential dampening of equipment demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConsolidation reduces supplier count, shifting leverage to buyers\u003c\/li\u003e\n\u003cli\u003eCentralized contracts = volume discount pressure but steadier revenue\u003c\/li\u003e\n\u003cli\u003eLow hospital margins (≈1.2% in 2024) may constrain equipment purchases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare margins squeezed: costs, wages, freight surge as rates lift debt burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic headwinds: medical PPI +6.2% YoY (2024), freight ~+12% vs 2022, technician wages +6–8% YoY, Medicaid\/clinic margins \u0026lt;3%, hospital operating margin ~1.2% (2024), home health spending $157B (2023) with 4.8% CAGR to 2028, Fed funds ~5.25% (2024) raising debt costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical PPI (2024)\u003c\/td\u003e\n\u003ctd\u003e+6.2% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFreight vs 2022\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTech wage growth\u003c\/td\u003e\n\u003ctd\u003e6–8% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome health spend (2023)\u003c\/td\u003e\n\u003ctd\u003e$157B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds (2024)\u003c\/td\u003e\n\u003ctd\u003e≈5.25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eInfuSystem PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact InfuSystem PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use with no placeholders or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752092873081,"sku":"infusystem-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/infusystem-pestle-analysis.png?v=1772237407","url":"https:\/\/matrixbcg.com\/products\/infusystem-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}